Neurological deficit in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis is widely considered to be a consequence of synergistic T and B cell responses to central nervous system (CNS) antigens. We show that mice immunized with encephalitogenic myelin oligodendrocyte glycoprotein ) peptide develop significant serum levels of anti-MOG antibodies in parallel with disease progression. Furthermore, EAE mice developed antibodies against DNA and RNA, a serological hallmark observed in autoimmune diseases such as systemic lupus erythematosus. The presence of anti-nucleic responsive B cells and antibodies during EAE may highlight a previously unappreciated mechanism in the pathogenesis of CNS autoimmunity.
Introduction
Multiple sclerosis (MS) is a relatively common disease with a complex etiology involving central nervous system (CNS) inflammation, demyelination and axonal damage. In occidental countries, MS affects about 0.1% of the population and is the first cause of disability of non-traumatic origin in young adults (Sospedra and Martin, 2005) . While MS has traditionally been considered to be a T-cell-mediated disease, there is an increasing body of evidence that B cells and autoantibodies may play a pathogenic role in this disease, providing a rationale for therapeutic approaches targeting B cells and B cell derived components of the immune system. B cells and plasma cells are commonly found in active MS plaques and the presence of cerebrospinal fluidspecific antibodies (oligoclonal bands) remains a hallmark finding in the diagnosis of MS (Noseworthy et al., 2000) . In addition, myelinspecific antibodies have been identified in areas of vesicular demyelination (Genain et al., 1999) , suggesting that they directly promote CNS damage, at least in a subset of MS patients (Lucchinetti et al., 2000) . Among these antibody responses, those directed against conformational epitopes of myelin-oligodendrocyte glycoprotein (MOG) are considered to be potentially pathogenic in MS (Lalive et al., 2006; Menge et al., 2007; Lalive, 2008; Lalive et al., 2011; Weber et al., 2011) .
Experimental autoimmune encephalomyelitis (EAE) is an animal model that recapitulates many clinical and pathological features of human MS. Immunization of C57BL/6 mice with MOG peptide amino acid (aa) ) alone has been shown to induce a chronic demyelinating disease predominantly driven by CD4 + Tcell-mediated immunity. The significance of myelin-specific antibodies in mediating myelin loss in this EAE model is controversial (Lalive, 2008) . As only B cell receptor (BCR) binding by native antigens initiates BCR signaling and a program of B-cell activation that ultimately results in B-cell differentiation and antibody production, it has generally been considered that production of MOG autoantibodies does not to take place in MOG 35-55 -induced EAE in a meaningful manner (Slavin et al., 2001) . A small body of evidence however points to a possible contribution of myelin-reactive antibodies to MOG 35-55 -induced EAE pathogenesis, and in particular T cell-dependent IgG1 and IgG2a antibody responses (Zhang et al., 2004) ; first, the benefit of B cell-depletion in MOG-induced EAE was associated with decreased antibody titers against MOG peptide (Matsushita et al., 2006) ; second, transfer of anti-MOG serum from MOG 35-55 -immunized mice has been demonstrated to increase severity of EAE in WT mice (Du and Sriram, 2002) . These studies imply that MOG peptide-specific antibodies and/or anti-MOG serum may be pathogenic in this strain, as it seems to be the case in several mouse and rat strains (Bernard et al., 1997) . According to some (Ichikawa et al., 1996a) but not all (Adelmann et al., 1995) investigations, Lewis rats immunized with MOG 35-55 can develop multifocal demyelinating disease despite the demonstration that these animals do not develop conformation-dependent anti-MOG antibodies (Ichikawa et al., 1996a (Ichikawa et al., , 1996b . Journal of Neuroimmunology 240-241 (2011) 28-33 
